Literature DB >> 19202572

Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression.

Jaime Kaufman1, Tanya A Griffiths, Michael G Surette, Susan Ness, Kevin P Rioux.   

Abstract

BACKGROUND: 5-Aminosalicylic acid (5-ASA) is a well-established treatment for inflammatory bowel disease (IBD) and may reduce the risk of colon cancer in patients with chronic colitis, but the mechanisms underlying these effects have not been fully elucidated. Although 5-ASA delivery is targeted to the distal gut, little is known about its effects on the luminal bacteria that reside there. Intestinal bacteria are believed play a role in causing or perpetuating IBD, and bioremediation has been studied as a therapeutic strategy. In an effort to better understand the bacteriological effects of 5-ASA, we examined the role of this compound at the level of bacterial gene expression.
METHODS: 5-ASA was screened for its effects on a random promoter library representing the genome of Salmonella enterica serovar Typhimurium as a model enteric bacterium. Forty-five constructs representing 38 unique promoters were found to be responsive to 5-ASA, and included genes involved in bacterial invasion, cellular metabolism, and stress resistance. Several genes of unknown function were also identified. These effects occurred at 5-ASA concentrations that are relevant to those achieved in the distal intestinal tract in patients with IBD but did not inhibit bacterial growth.
RESULTS: Bacterial invasiveness was decreased by 5-ASA. Some of the identified genes had homologs among commensal Gram-negative enteric bacteria.
CONCLUSIONS: This study demonstrates that 5-ASA has potent effects on bacterial gene expression. These novel findings implicate intestinal bacteria as pharmacological targets of 5-ASA, perhaps contributing to the therapeutic action of this important class of IBD drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19202572     DOI: 10.1002/ibd.20876

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  14 in total

Review 1.  MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis.

Authors:  Lily P H Yang; Paul L McCormack
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Gut microbiota in the pathogenesis of inflammatory bowel disease.

Authors:  Atsushi Nishida; Ryo Inoue; Osamu Inatomi; Shigeki Bamba; Yuji Naito; Akira Andoh
Journal:  Clin J Gastroenterol       Date:  2017-12-29

3.  IBD 2009: emerging research frontiers on the path to a cure.

Authors:  A Hillary Steinhart; G Tolomiczenko
Journal:  Can J Gastroenterol       Date:  2010-09       Impact factor: 3.522

4.  A review of the biological and pharmacological activities of mesalazine or 5-aminosalicylic acid (5-ASA): an anti-ulcer and anti-oxidant drug.

Authors:  Mohammad Beiranvand
Journal:  Inflammopharmacology       Date:  2021-08-19       Impact factor: 4.473

5.  Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.

Authors:  Glen A Doherty; Mark A Peppercorn
Journal:  Clin Exp Gastroenterol       Date:  2009-12-08

Review 6.  Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth.

Authors:  L Gatta; C Scarpignato
Journal:  Aliment Pharmacol Ther       Date:  2017-01-12       Impact factor: 8.171

7.  Iron Sequestration in Microbiota Biofilms As A Novel Strategy for Treating Inflammatory Bowel Disease.

Authors:  Jean-Paul Motta; Thibault Allain; Luke E Green-Harrison; Ryan A Groves; Troy Feener; Hena Ramay; Paul L Beck; Ian A Lewis; John L Wallace; Andre G Buret
Journal:  Inflamm Bowel Dis       Date:  2018-06-08       Impact factor: 5.325

8.  VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice.

Authors:  Chun-Sai-Er Wang; Wen-Bin Li; Hong-Ying Wang; Yi-Ming Ma; Xin-Hua Zhao; Hong Yang; Jia-Ming Qian; Jing-Nan Li
Journal:  World J Gastroenterol       Date:  2018-10-07       Impact factor: 5.742

9.  A Dietary Cholesterol-Based Intestinal Inflammation Assay for Improving Drug-Discovery on Inflammatory Bowel Diseases.

Authors:  Nuno-Valério Silva; Diogo Carregosa; Catarina Gonçalves; Otília V Vieira; Cláudia Nunes Dos Santos; António Jacinto; Carolina Lage Crespo
Journal:  Front Cell Dev Biol       Date:  2021-06-03

10.  Characterization of adherent bacteroidales from intestinal biopsies of children and young adults with inflammatory bowel disease.

Authors:  Naamah L Zitomersky; Benjamin J Atkinson; Sarah W Franklin; Paul D Mitchell; Scott B Snapper; Laurie E Comstock; Athos Bousvaros
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.